Hemophilia
Conditions
Brief summary
This study will assess the pharmacokinetics and pharmacodynamics of rhFVIIa at three dose levels. The results will help identify the most optimal doses to take forward to the Phase 2/3 studies where bleedings in hemophilia patients with inhibitors will be treated with rhFVIIa.
Interventions
BIOLOGICALrhFVIIa
Patients will be administered low, intermediate and high doses of rhFVIIa
Sponsors
rEVO Biologics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. be male with a diagnosis of moderate or severe congenital hemophilia A and/or B (with or without inhibitors) 2. be 18 years or older, up to and including 75 years of age 3. be capable of understanding and willing to comply with the conditions of the protocol 4. have read, understood and provided written informed consent
Exclusion criteria
1. have any coagulation disorder other than hemophilia A or B 2. have a body weight \>105 kg (231 lb) 3. be immuno-suppressed (i.e., the patient should not receive systemic immunosuppressive medication \<30 days prior to enrollment, CD4 counts at screening should be \>200/µl) 4. have a known allergy or hypersensitivity to rabbits 5. have platelet count \<100,000/mL 6. have had within one month prior to first administration of the study drug in this study a major surgical procedure (e.g. orthopedic, abdominal) 7. have an active, ongoing bleeding for which the patient is being treated, or treatment for a bleeding was stopped within 24 hours of the time of study drug administration 8. have received a Factor VII or FVIIa containing product (either plasma derived or recombinant) within 72 hours prior to any study drug administration 9. have received an investigational drug within 30 days of the first study drug administration, or is expected to receive such drug during participation in this study 10. have a clinically relevant hepatic (hepatic enzymes \>3 times the upper limit of normal) and/or renal impairment (creatinine \>2 times the upper limit of normal) 11. have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or pulmonary embolism) within 2 years prior to first dose of study drug, have an arterial stent in place or have clinically significant atherosclerotic disease (e.g., angina pectoris, peripheral vascular disease) 12. use any anticoagulant for arterial/venous obstructions and/or atrial fibrillation within 7 days prior to first study drug administration 13. have an active malignancy (those with non-melanoma skin cancer are allowed) 14. have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Factor VIIa concentration in patient plasma as measured by FVIIa PK and PD assays | Up to 36 hours of dosing |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of patients with treatment emergent adverse events | Up to 28 days after dosing |
Countries
Netherlands, United States
Outcome results
None listed